CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer SymposiumTM (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC)

ROCKVILLE, Md., Dec. 1, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs announces a poster presentation on ENMD-2076 at the 2017 San Antonio Breast Cancer Symposium^TM (SABCS), December 5-9, 2017 in San Antonio, Texas. 

ENMD-2076 is currently in a Phase 2 trial for the treatment of triple-negative breast cancer (TNBC) at two locations in the U.S. The poster will be presented in the session listed below and will be available on the CASI Pharmaceuticals website after the conclusion of the presentation.

Program Number: PD3-16
Abstract Number: 272
Session Title: Novel Drugs / Predicting Response for HER2+ Breast Cancer
Session Date: Thursday, December 7, 2017
Session Time: 7:00:00 AM ? 9:00:00 AM CST
Title: "Clinical Safety and Efficacy of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated, Locally Advanced or Metastatic Triple-Negative Breast Cancer"

About CASI Pharmaceuticals, Inc.

CASI is a U.S. based, late-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a focus on commercialization in China. CASI's product pipeline features (1) EVOMELA^®, MARQIBO^® and ZEVALIN^®, all U.S. Food and Drug Administration (FDA) approved drugs in-licensed from Spectrum Pharmaceuticals, Inc. for China regional rights, and currently in various stages in the regulatory and clinical process for market approval in China, (2) CASI-001 and CASI-002, proprietary preclinical candidates in immune-oncology, and (3) our proprietary drug candidate, ENMD-2076, ongoing in one Phase 2 clinical study. CASI is headquartered in Rockville, Maryland and has a wholly owned subsidiary and R&D operations in Beijing, China. More information on CASI is available at www.casipharmaceuticals.com and in CASI's filings with the U.S. Securities and Exchange Commission.

CASI's China rights to EVOMELA^® (melphalan) for Injection, MARQIBO^® (vinCRIStine sulfate LIPOSOME injection) and ZEVALIN^® (ibritumomab tiuxetan) were previously licensed from its partner Spectrum Pharmaceuticals, Inc. Based on the U.S. FDA's approval of these three licensed products, CASI is pursuing the Import Drug registration path for approval in China. 

Forward Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including: that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the volatility in the market price of our common stock; risks relating to interests of our largest stockholders that differ from our other stockholders; the risk of substantial dilution of existing stockholders in future stock issuances, the difficulty of executing our business strategy in China; our inability to predict when or if our product candidates will be approved for marketing by the China Food and Drug Administration authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; risks associated with our product candidates; risks associated with any early-stage products under development; the risk that results in preclinical and early clinical models are not necessarily indicative of later clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks). Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

EVOMELA^®, MARQIBO^® and ZEVALIN^® are proprietary to Spectrum Pharmaceuticals, Inc. and its affiliates.

SOURCE CASI Pharmaceuticals, Inc.